title: Treatment of Crohn's disease patients with infliximab is detrimental for the survival of Mycobacterium avium ssp. paratuberculosis within macrophages and shows a remarkable decrease in the immunogenicity of mycobacterial proteins.
authors.forename: Horacio
authors.initials: H
authors.lastname: Bach
authors.forename: Greg
authors.initials: G
authors.lastname: Rosenfeld
authors.forename: Brian
authors.initials: B
authors.lastname: Bressler
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D001426:Bacterial Proteins / Q000276:immunology* / Q000378:metabolism; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D055261:Immunogenetic Phenomena; D000069285:Infliximab; D008264:Macrophages / Q000276:immunology* / Q000378:metabolism / Q000382:microbiology; D016927:Mycobacterium avium subsp. paratuberculosis / Q000378:metabolism*; D010283:Paratuberculosis / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D001426:Bacterial Proteins; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab